与cuproptosis相关的长非编码RNA预测了整体存活率,并揭示了膀癌的免疫微环境
Haoran Wang1,2, Zhengtong Lv1,2, Haoran Xia1,2
1Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 DaHua Road, Dong Dan, Beijing, 100730, China.
Heliyon
|December 14, 2023
概括
研究人员开发了一种新的风险模型,使用7种与cuproptosis相关的长非编码RNA (lncRNAs) 来预测膀癌的预后和免疫反应. 该模型有助于评估患者的治疗结果,并指导治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞死亡研究 细胞死亡研究
- 分子生物学分子生物学
背景情况:
- 铜亡是一种新发现的,依赖于铜的编程细胞死亡途径.
- 长非编码RNAs (lncRNAs) 在膀癌预后中发挥作用.
- 这项研究重点关注膀癌中与cuproptosis相关的lncRNAs.
研究的目的:
- 建立基于与cuproptosis相关的lncRNAs的评分系统,用于预测膀癌的预后.
- 用这个评分系统来分析膀癌的免疫格局.
- 评估风险模型在指导综合治疗策略方面的潜力.
主要方法:
- 利用了癌症基因组图谱 (TCGA) 对431个膀癌组织的数据.
- 通过COX和LASSO回归开发了一个风险模型,使用7种与cuproptosis相关的lncRNA.
- 用卡普兰-梅尔曲线,ROC分析和名ograms评估模型准确性.
- 使用ssGSEA,ESTIMATE和途径分析分析了免疫透,基因突变和药物敏感性.
主要成果:
- 构建了一个风险模型,其中包括7个与cuproptosis相关的lncRNAs (LINC01184,LINC00513,LINC02443,SMARCA5-AS1,BDNF-AS,SOD2-OT1,HYI-AS1).
- 该模型准确地预测了不同阶段的膀癌患者的整体存活率.
- 在高风险和低风险组之间观察到免疫透和药物敏感性的显著差异.
结论:
- 一个新的与cuproptosis相关的lncRNA风险模型有效地预测了膀癌的预后和免疫治疗反应.
- 这种模型为膀癌的预后评估提供了新的见解.
- 这些发现可能会为膀癌患者的个性化治疗方法提供指导.
更多相关视频
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K


